Navigation Links
Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
Date:6/8/2008

For each subject, the trial is expected to take 14.5 months: 2.5 months for screening and subject treatment and a further 12 months for subject follow-up. Individuals interested in participating in this trial should visit http://www.clinicaltrials.gov/ .

About Diabetic Neuropathy

Diabetic peripheral neuropathy is one of the most frequent complications of diabetes. Symptoms include numbness, tingling sensations and pain particularly in the toes or feet. This gradually evolves to loss of sensation and motor function as nerve damage progresses. Ulcers and sores may appear on numb areas of the foot because pressure or injury goes unnoticed. Despite adequate treatment, these areas of trauma frequently become infected and this infection may spread to the bone, necessitating amputation of the leg or foot. More than 60 percent of non-traumatic lower-limb amputations in the United States occur among people with diabetes. In the period from 2000 to 2001, this translated to approximately 82,000 amputations. The American Diabetes Association estimates that there are approximately 20.8 million people with diabetes in the United States and that of those about 60 percent to 70 percent have mild to severe forms of neuropathy. According to the Centers for Disease Control, diabetes is becoming more common in the United States. From 1980 through 2002, the number of Americans with diabetes more than doubled.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused o
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
2. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
3. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
4. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
5. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
6. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
7. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
8. Magellan Biosciences Companies to Feature Automated Products and New Tests for MRSA at the American Society for Microbiology Meeting, Booth 743
9. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
10. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
11. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... to Millennium Research Group (MRG), the global authority ... United States and European transcatheter embolization ... through 2022, with embolization particles representing one of ... drug-eluting beads (DEBs) and radioembolization spheres in interventional ...
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: Global ... Systems -- Focus on End Users ... OBJECTIVES A drug delivery system ...
(Date:1/14/2014)... Mass. , Jan. 14, 2014 HeartWare ... leading innovator of less invasive, miniaturized circulatory support technologies ... today announced that it expects revenues for the fourth ... expected full-year 2013 revenues to approximately $208 million. ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... PHILADELPHIA, Jan. 20, 2011 The U.S. Food ... System Drugs Advisory Committee decided today that it ... this time based on the currently available data ... of Amyvid conditional on a reader training program ...
... Inc. (Nasdaq: ELGX ), developer of minimally invasive ... release of its fourth quarter and full year 2010 financial ... after the close of the market. Endologix will ... 5:00 p.m. ET / 2:00 p.m. PT to discuss the ...
Cached Medicine Technology:Statement from Lilly and Avid on FDA Advisory Committee Recommendation for Amyvid™ (Florbetapir) NDA 2Endologix to Report Fourth Quarter and Full Year 2010 Financial Results on February 22, 2011 2
(Date:7/9/2014)... For the first time, researchers have access to detailed ... uses health care. A new study, called Our Health ... unique challenges faced by urban Aboriginal people in Canada ... , The findings, published today in BMJ Open ... and the general population. , Researchers interviewed 554 First ...
(Date:7/9/2014)... hidden ways that cells are regulated, scientists at Rockefeller ... cells more likely to metastasize. , What,s more, the ... blocking two other proteins that are normally linked to ... could have unexpected ties. , The study, which ... , points to the possibility of new cancer therapies ...
(Date:7/9/2014)... in policing injection drug users in Russia might ... , A study, conducted by researchers from Boston ... collaboration with St. Petersburg Pavlov State University, sought ... the health outcomes of a cohort of HIV-positive ... Those who were arrested by police were more ...
(Date:7/9/2014)... YORK (July 8, 2014) Researchers from Montefiore ... of Medicine of Yeshiva University will present new ... held July 12 July 17 in Copenhagen, Denmark. ... that could prompt transition from cognitive normality to mild ... the Einstein Aging Study , established in 1980 ...
(Date:7/9/2014)... The liver is one of the most important organs ... that we utilize our food properly this is ... removed from our organism this is its detoxification ... and unhealthy food all damage the liver. The resulting ... deposits, cirrhoses, and life-threatening liver failure. According to the ...
Breaking Medicine News(10 mins):Health News:Urban Aboriginal people face unique health challenges 2Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3Health News:BU researchers relate arrests with HIV risk environment 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3Health News:Telemedicine for patients with chronic liver diseases 2Health News:Telemedicine for patients with chronic liver diseases 3
... 3, 2007) Two methods that permit scientists ... in this months release of Cold Spring Harbor ... online ( www.cshprotocols.org ), describe how to fluorescently tag ... combined with sophisticated imaging methods, permit scientists to visualize ...
... with Las Vegas and Tucson Marathon Runners, PLEASANT ... an event to prevent inflammation and pain, but at ... by researchers at,Appalachian State University and Vanderbilt University, published ... taking ibuprofen,before exercise may be unhealthy in the long ...
... to,build on the issue of requiring physicians to ... Management Association,(PCMA) today announced a new round of ... Last year, Dr. Bootman co-chaired an Institute of ... using e-prescribing by,2010 to help reduce the estimated ...
... ... -, JEFFERSON CITY, Mo., ... -,Missouri Military Family Relief Fund, which will help support the needs of,more than ... for the central market area at,TriWest, will present the check to the Adjutant ...
... Dec. 3 Operon,Biotechnologies, Eurofins MWG and Eurofins ... - announced today that they have agreed to ... leader in the competitive,custom oligonucleotide market. With about ... high-throughput production facilities in all major markets (North,America, ...
... retires; Mike Gallagher, President and CEO of ... Dec. 3 AvMed Health Plans said today ... to retire December 31,2007. As a result, Mike ... HealthCare, who already has overall leadership and strategic,responsibilities ...
Cached Medicine News:Health News:Cold Spring Harbor Protocols features innovative methods for embryology research 2Health News:Marathoners Share Tom Brady and LaDainian Tomlinson Pain Relief Affinity 2Health News:TriWest Contributes $15,000 to Missouri National Guard Fund 2Health News:MWG and Operon Are Joining Forces 2Health News:AvMed Announces Senior Leadership Changes 2
For use with cushioned neckband....
... PVC siliconized. Stainless steel spiral reinforced. X-ray ... use. Adjustable Flange: The flange can be ... the thickness of the cervical soft tissue. ... the flange is tightly connected to the ...
... The permanent flexible tube ... of the neck flange helps ... neck, chin, and stoma, enhancing ... ,Bivona® FlexTend™ tracheostomy tubes ...
Aire-Cuf® tracheostomy tubes are ideal for short-term to medium-term ventilator support....
Medicine Products: